The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome
M Moros, SG Mitchell, V Grazu - Current Medicinal Chemistry, 2013 - ingentaconnect.com
Many pharmaceuticals on the market suffer from two significant limitations to their activity:
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome
M Moros, SG Mitchell, V Grazú… - Current medicinal …, 2013 - pubmed.ncbi.nlm.nih.gov
Many pharmaceuticals on the market suffer from two significant limitations to their activity:
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
[PDF][PDF] The Fate of Nanocarriers As Nanomedicines In Vivo: Important Consid-erations and Biological Barriers to Overcome
M Moros, SG Mitchell, V Grazú… - Current Medicinal …, 2013 - researchgate.net
Many pharmaceuticals on the market suffer from two significant limitations to their activity:
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
The fate of nanocarriers as nanomedicines in vivo: important considerations and biological barriers to overcome.
M Moros, SG Mitchell, V Grazú… - Current Medicinal …, 2013 - europepmc.org
Many pharmaceuticals on the market suffer from two significant limitations to their activity:
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …
lack of specificity toward the pathological site and poor aqueous solubility. Both factors …